Filing Flows › Integra Lifesciences Holdings (IART) › Q3 2026 › vs Q3 2025
Integra Lifesciences Holdings (IART) Q3 2026 vs Q3 2025 (year over year)
Integra Lifesciences Holdings's revenue rose $9.1M (+2%) from $402M in Q3 2025 to $411M in Q3 2026. The biggest changes: Specialty Surgery +$11.5M (+4%); Tissue Reconstruction −$2.4M (-2%). Operating margin 4.6% against 2.9% (+1.7 pts).
Integra Lifesciences Holdings, Q3 2026: revenue $411M (+2% year over year), operating margin 4.6%, net earnings $14.9M, operating cash flow $96.0M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 4.6% | 2.9% | +1.7 pts |
| Net margin | 3.6% | -1.3% | +5.0 pts |
| Free cash flow margin | 20.8% | 6.4% | +14.4 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Specialty Surgery | $304M | $293M | $11.5M | +4% |
| Tissue Reconstruction | $107M | $109M | −$2.4M | -2% |
| Revenue | $411M | $402M | $9.1M | +2% |
| Operating profit | $18.9M | $11.8M | $7.1M | +61% |
| Costs & expenses | $392M | $390M | $2.0M | +0.5% |
| Pre-tax earnings | $15.7M | −$6.8M | $22.5M | — |
| Other expense, net | $3.2M | $18.6M | −$15.3M | -83% |
| Cost of revenue | $201M | $195M | $6.2M | +3% |
| Research & development | $21.9M | $22.5M | −$559K | -2% |
| SG&A | $165M | $169M | −$3.7M | -2% |
| Other operating costs | $3.8M | $3.7M | $30K | +0.8% |
| Net earnings | $14.9M | −$5.4M | $20.3M | — |
| Income tax | $812K | −$1.4M | $2.2M | — |
| Share-based compensation | $2.9M | $5.6M | −$2.7M | -48% |
| Working capital & other | $78.2M | $40.7M | $37.5M | +92% |
| Operating cash flow | $96.0M | $40.9M | $55.1M | +135% |
| Free cash flow (company-reported) | $85.7M | $25.8M | $60.0M | +233% |
| Purchases of property and equipment | $10.2M | $15.2M | −$4.9M | -32% |
Questions
How much did Integra Lifesciences Holdings's revenue grow year over year in Q3 2026?
Integra Lifesciences Holdings's revenue rose $9.1M (+2%) from $402M in Q3 2025 to $411M in Q3 2026.
What drove Integra Lifesciences Holdings's revenue change in Q3 2026?
Specialty Surgery +$11.5M (+4%); Tissue Reconstruction −$2.4M (-2%).